Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Cullinan Therapeutics (CGEM) Shares Outstanding (Weighted Average) (2020 - 2023)

Cullinan Therapeutics has reported Shares Outstanding (Weighted Average) over the past 4 years, most recently at $42.7 million for Q3 2023.

  • Quarterly results put Shares Outstanding (Weighted Average) at $42.7 million for Q3 2023, down 4.96% from a year ago — trailing twelve months through Sep 2023 was $42.7 million (down 4.96% YoY), and the annual figure for FY2022 was $45.2 million, up 4.84%.
  • Shares Outstanding (Weighted Average) for Q3 2023 was $42.7 million at Cullinan Therapeutics, up from $40.0 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for CGEM hit a ceiling of $45.2 million in Q4 2022 and a floor of $18.7 million in Q1 2020.
  • Median Shares Outstanding (Weighted Average) over the past 4 years was $42.7 million (2023), compared with a mean of $36.8 million.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): surged 126.49% in 2021 and later dropped 10.97% in 2023.
  • Cullinan Therapeutics' Shares Outstanding (Weighted Average) stood at $19.9 million in 2020, then skyrocketed by 116.61% to $43.1 million in 2021, then grew by 4.84% to $45.2 million in 2022, then fell by 5.38% to $42.7 million in 2023.
  • The last three reported values for Shares Outstanding (Weighted Average) were $42.7 million (Q3 2023), $40.0 million (Q2 2023), and $40.7 million (Q1 2023) per Business Quant data.